Shipped cold to your door  ·  Lyophilized vialsQuestions? WhatsApp +62 811 2120 5090
A couple sitting side by side enjoying the sunset
Hormones

PT-141 (bremelanotide): how it works in the brain and its FDA approval

15 October 2026

PT-141 is the research code name for bremelanotide, a peptide that works on melanocortin receptors in the central nervous system. What makes it stand out: in the United States, bremelanotide was approved by the FDA in June 2019 under the brand Vyleesi for premenopausal women with low sexual desire disorder. This article covers its origin, how it works, and what its clinical trials contain.

From a skin-tanning peptide to desire research

Bremelanotide was born from Melanotan II, a peptide first studied at the University of Arizona as a skin-tanning agent. In its early studies an effect on sexual desire was observed, and the direction of the research shifted. Palatin Technologies then developed bremelanotide, a molecule very similar to Melanotan II, specifically for sexual function.

Its first version was a nasal spray and was tested in men with erectile dysfunction as well as in women. Development was then focused on women, in the form of an injection under the skin.

How it works in the brain

According to the FDA label, bremelanotide activates several types of melanocortin receptor, and the most relevant are MC4R and MC1R. MC4R is found widely in the central nervous system, including areas that regulate motivation and sexual response. MC1R is in the pigment cells of the skin.

This is different from common erectile dysfunction medicines, which work by widening blood vessels. The target of PT-141 is the desire signal in the brain, and this approach is what makes it interesting.

Inside the phase 3 RECONNECT trials

The FDA approval rests on two identical phase 3 trials known as RECONNECT. Both trials were randomized, double-blind, used a comparison group, ran for 24 weeks, and involved around 1,250 premenopausal women with acquired low sexual desire disorder that had lasted at least six months.

Desire
Desire scores rose more than in the comparison group in both trials.
Distress
Distress caused by low desire fell more than in the comparison group.

What some users feel

Some people feel mild nausea or brief facial flushing, and PT-141 is not for people with high blood pressure or heart disease.

If you are also reading about other peptides in the hormone group, how its pathway differs from Kisspeptin is covered in Kisspeptin: the first signal in the hormone chain. The checklist for buying peptides online safely can help you put together questions before ordering.

The product details are in the Peptivia catalog. If there is anything you would like to ask before ordering, the Peptivia team is ready to help through Peptivia's official WhatsApp.

Frequently asked questions
Is PT-141 the same as bremelanotide?

Yes. PT-141 is the research code name, bremelanotide is the name of the substance, and Vyleesi is the brand of the medicine approved in the United States in 2019.

Has PT-141 ever been studied in men?

Yes. The nasal spray version was tested in men with erectile dysfunction up to phase 2. The 2019 FDA approval is intended for premenopausal women with low sexual desire.

How is PT-141 different from common erectile dysfunction medicines?

Common erectile dysfunction medicines work by widening blood vessels. PT-141 works in the brain through melanocortin receptors, mainly MC4R, which is found in the areas that regulate motivation and sexual response.

Peptides in this article

Still deciding which one fits? Tell us your goal and we will help you narrow it down.

Chat on WhatsApp